| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $2,785,303 | 21 | 100 |
| Feld Michael | EVP, CRO & Pres. Life Sciences | 0 | $0 | 12 | $175,276 | $-175,276 |
| SCOTT BERTRAM L | director | 0 | $0 | 2 | $212,345 | $-212,345 |
| Goette Roland | EVP and President, EMEA | 0 | $0 | 1 | $440,888 | $-440,888 |
| Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | 0 | $0 | 4 | $784,162 | $-784,162 |
| Polen Thomas E Jr | Chairman, CEO and President | 0 | $0 | 2 | $1.17M | $-1.17M |
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products …
Over the last 12 months, insiders at Becton, Dickinson and Company have bought $0 and sold $2.79M worth of Becton, Dickinson and Company stock.
On average, over the past 5 years, insiders at Becton, Dickinson and Company have bought $1.36M and sold $4.1M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,250 shares for transaction amount of $1.01M was made by HAYES GREGORY (director) on 2025‑08‑11.
| 2026-10-26 | Sale | Feld Michael | EVP, Chief Revenue Officer | 76 <0.0001% | $198.13 | $15,058 | +0.83% | |
| 2026-09-28 | Sale | Feld Michael | EVP, Chief Revenue Officer | 76 <0.0001% | $183.70 | $13,961 | +4.03% | |
| 2026-08-26 | Sale | Feld Michael | EVP, Chief Revenue Officer | 165 <0.0001% | $188.49 | $31,101 | -2.57% | |
| 2026-08-13 | Sale | Polen Thomas E Jr | Chairman, CEO and President | 4,152 0.0015% | $185.00 | $768,120 | +2.83% | |
| 2026-08-11 | Sale | Goette Roland | EVP and President, EMEA | 2,438 0.0009% | $180.84 | $440,888 | +2.49% | |
| 2026-07-27 | Sale | Feld Michael | EVP, Chief Revenue Officer | 75 <0.0001% | $157.13 | $11,785 | +16.14% | |
| 2026-06-26 | Sale | Feld Michael | EVP, Chief Revenue Officer | 75 <0.0001% | $152.80 | $11,460 | +17.02% | |
| 2026-06-24 | Sale | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | 1,100 0.0003% | $145.66 | $160,226 | +23.32% | |
| 2026-06-10 | Sale | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | 1,100 0.0003% | $151.48 | $166,628 | +22.72% | |
| 2026-06-01 | Sale | Polen Thomas E Jr | Chairman, CEO and President | 2,764 0.0008% | $146.35 | $404,511 | +25.06% | |
| 2026-05-26 | Sale | Feld Michael | EVP, Chief Revenue Officer | 75 <0.0001% | $147.35 | $11,051 | +22.75% | |
| 2026-04-27 | Sale | Feld Michael | EVP, Chief Revenue Officer | 74 <0.0001% | $151.94 | $11,244 | +13.46% | |
| 2026-03-26 | Sale | Feld Michael | EVP, Chief Revenue Officer | 75 <0.0001% | $156.83 | $11,762 | +0.05% | |
| 2026-02-26 | Sale | Feld Michael | EVP, Chief Revenue Officer | 75 <0.0001% | $181.84 | $13,638 | -9.32% | |
| 2026-02-18 | Sale | SCOTT BERTRAM L | director | 953 0.0003% | $182.61 | $174,027 | -12.06% | |
| 2026-01-26 | Sale | Feld Michael | EVP, CRO & Pres. Life Sciences | 75 <0.0001% | $202.73 | $15,205 | +1.34% | |
| 2026-01-15 | Sale | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | 1,610 0.0006% | $207.46 | $334,005 | -1.11% | |
| 2025-12-26 | Sale | Feld Michael | EVP, CRO & Pres. Life Sciences | 74 <0.0001% | $196.08 | $14,510 | +4.21% | |
| 2025-12-17 | Sale | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | 629 0.0002% | $196.03 | $123,303 | +4.34% | |
| 2025-12-01 | Sale | Feld Michael | EVP, CRO & Pres. Life Sciences | 75 <0.0001% | $193.36 | $14,502 | +6.41% |
| OVERLOCK WILARD J JR | director | 21091 0.0077% | $4.18M | 2 | 2 | +1.24% |
| UGGLAS MARGERETHA AF | director | 10000 0.0037% | $1.98M | 1 | 0 | +22.51% |
| BURZIK CATHERINE M | director | 10007 0.0037% | $1.98M | 3 | 1 | +5.52% |
| Henderson Jeffrey William | director | 8015 0.0029% | $1.59M | 1 | 0 | <0.0001% |
| HAYES GREGORY | director | 6046 0.0022% | $1.2M | 1 | 0 | +2.27% |
| Minehan Cathy E. | director | 3000 0.0011% | $594,510.00 | 2 | 0 | +2.03% |
| Melcher David F | director | 2728 0.001% | $540,607.76 | 1 | 0 | +8.76% |
| Increased Positions | 678 | +36.57% | 26M | +9.79% |
| Decreased Positions | 819 | -44.17% | 19M | -7.31% |
| New Positions | 213 | New | 4M | New |
| Sold Out Positions | 131 | Sold Out | 5M | Sold Out |
| Total Postitions | 1,713 | -7.61% | 269M | +2.47% |
| Vanguard Group Inc | $6.33M | 11.39% | 32.46M | +147,041 | +0.46% | 2025-09-30 |
| Blackrock, Inc. | $5.41M | 9.74% | 27.75M | +472,432 | +1.73% | 2025-09-30 |
| T. Rowe Price Investment Management, Inc. | $3.16M | 5.7% | 16.23M | +54,113 | +0.33% | 2025-09-30 |
| State Street Corp | $2.7M | 4.87% | 13.87M | +459,219 | +3.42% | 2025-09-30 |
| First Eagle Investment Management, Llc | $1.95M | 3.51% | 9.99M | +1M | +13.75% | 2025-09-30 |
| Massachusetts Financial Services Co /Ma/ | $1.78M | 3.21% | 9.15M | +636,138 | +7.47% | 2025-09-30 |
| Geode Capital Management, Llc | $1.33M | 2.4% | 6.83M | +107,775 | +1.6% | 2025-09-30 |
| Franklin Resources Inc | $1.31M | 2.36% | 6.74M | +4M | +150.85% | 2025-09-30 |
| Jpmorgan Chase & Co | $1.03M | 1.86% | 5.29M | +743,678 | +16.37% | 2025-09-30 |
| Wellington Management Group Llp | $1.02M | 1.84% | 5.23M | +5M | +9,056.29% | 2025-09-30 |